Screener
Insulet PODD R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Insulet’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001145197-26-000169
| (in millions, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 801.7 | 649.1 | 1,563.4 | 1,218.1 |
| Cost of revenue | 239.1 | 196.9 | 471.8 | 356.8 |
| Gross profit | 562.6 | 452.2 | 1,091.6 | 861.3 |
| Research and development expenses | 88.1 | 73.4 | 177.8 | 133.0 |
| Selling, general and administrative expenses | 344.8 | 257.7 | 662.1 | 518.4 |
| Operating income | 129.7 | 121.1 | 251.8 | 209.9 |
| Interest expense | (13.5) | (19.6) | (28.2) | (28.8) |
| Interest income | 3.6 | 10.1 | 8.5 | 20.3 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Insulet's R&D?
- Insulet (PODD) reported R&D of $88.1M in Q2 2026.
- How has Insulet's R&D changed year-over-year?
- Insulet's R&D increased by 20.0% year-over-year, from $73.4M to $88.1M.
- What is the long-term trend for Insulet's R&D?
- Over 4 years (2021 to 2025), Insulet's R&D has grown at a 17.1% compound annual growth rate (CAGR), from $160.1M to $301.1M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Insulet's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude